NR3C2 and chronic kidney disease: Mineralocorticoid receptor antagonist (MRA) therapy has been suggested to mitigate renal fibrosis.[5,6] MRA decreased proteinuria in CKD subjects by up to 23% to 61%[7,8] and lowered biomarkers associated with CKD progression in rats, e.g. tissue expression of Type I and III collagen [9].